Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics (AKTX)
NASDAQ:AKTX
Holding AKTX?
Track your performance easily
AKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $4.40
Previous Close$1.47
Volume178.05K
Average Volume (3M)21.98K
Market Cap
$19.07M
Enterprise Value$15.87M
Total Cash (Recent Filing)$4.20M
Total Debt (Recent Filing)$1.00M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Apr 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,758,558
10 Day Avg. Volume50,200
30 Day Avg. Volume21,982
Standard Deviation0.21
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-4.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Akari Therapeutics News
PremiumCompany Announcements
Akari Therapeutics Advances Post-Merger with Strategic Moves
PremiumCompany Announcements
Akari Therapeutics Merges with Peak Bio for Growth
PremiumCompany Announcements
Akari Therapeutics Merges with Peak Bio to Advance Autoimmune Treatments
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $1.08 and its highest was $4.40 in the past 12 months.
What is Akari Therapeutics’s market cap?
Currently, no data Available
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 08, 2025 which is in 137 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 19, 2024. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 24,758,558 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -0.278%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
---
Akari Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Akari Therapeutics
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
---
Technical Analysis
---